Accelerated By Radioisotopes Revolutionizing Cancer Treatment The Global Alpha Emitter Market To Witness Significant Growth
Alpha Emitter Market |
Alpha emission therapy has
emerged as a promising targeted cancer therapeutics approach, utilizing
radioactive atoms known as alpha emitters that can selectively kill cancerous
cells while sparing surrounding healthy tissues. Alpha emitters work by
emitting highly potent alpha particles as they decay, capable of cell
destruction within the range of only a few cell diameters. This enables
unprecedented specificity for eliminating tumors while minimizing harm to
nearby healthy cells. The ability to deliver alpha emitters directly to tumor
sites using molecularly-targeted carrier molecules has revolutionized cancer
treatment. The global Alpha Emitter Market size is estimated to be valued at US$ 1,331.0 Mn in 2023 and is expected
to exhibit a CAGR of 10% over the
forecast period 2023 to 2030, as highlighted in a new report published by
Coherent Market Insights.
Market key trends:
The increasing success of
actinium-225 and bismuth-213 based targeted alpha therapy in clinical trials is
one of the primary drivers accelerating growth of the alpha emitter market.
Actinium-225 and bismuth-213 can be attached to tumor-targeting molecules and
delivered locally to eliminate cancerous cells. Ongoing research seeks to
develop additional alpha emitter generators as well as monoclonal antibodies
and peptides to selectively transport these radioactive atoms and precisely
target tumors. As targeted alpha therapy demonstrates encouraging efficacy with
minimal side effects, adoption is expected to rise significantly over the
coming years. This will be crucial in advancing alpha emitter market expansion.
Segment Analysis
The global alpha emitter market
is dominated by targeted alpha therapy (TAT) sub segment. TAT is the most
promising segment as it holds potential to treat cancer effectively by
targeting cancer cells precisely using alpha emitting radiopharmaceuticals
while sparing normal tissues. TAT could greatly improve outcomes for cancer
patients by selectively delivering highly potent alpha particles to tumors.
Key Takeaways
The Global
Alpha Emitter Market Share is expected to witness high growth over the
forecast period of 2023 to 2030. The rising incidence of cancer worldwide along
with benefits offered by alpha emitter therapies is fueling the market growth.
Regional analysis: North America region currently dominates the
global alpha emitter market and is expected to continue its dominance during the
forecast period. Higher adoption of advanced cancer therapies along with
presence of major players in the region is driving the market. Asia Pacific
region is expected to be the fastest growing market during the forecast period
owing to increasing healthcare spending and rising awareness about alpha
emitter therapies in the region.
Key players: Key
players operating in the alpha emitter market are Actinium Pharmaceutical Inc.,
Alpha Tau Medical Ltd, Bayer AG, Bracco, Cardinal Health, Eckert & Ziegle,
Fusion Pharmaceuticals, IBA Worldwide, NorthStar Medical Radioisotopes (NMR),
Orano Group, Viewpoint Molecular Targeting, RadioMedix, Telix Pharmaceuticals
Limited., TerraPower, LLC, NIOWAVE Inc. and IONETIX Corporation. Actinium
Pharmaceutical Inc. currently dominates the market.
Get More Insights Here
https://www.newsstatix.com/alpha-emitter-market-size-share-growth-outlook-2023/
Comments
Post a Comment